Teva gets a taste of its own patent-challenge medicine

Teva Pharmaceutical Industries, the generic-drug giant that made a business out of challenging the valuable patents of Big Pharma, is getting a taste of its own tactics as generics makers target its multiple sclerosis drug Copaxone. And it's adopting the same defensive tactics that branded drugmakers have employed against it for years. Report

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease..

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opidivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”